B

이오플로우

294090KOSDAQ

57.5 / 100

Reference Date: 2026-10-23

Financial Score20.0 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure15.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

EoFlow is a medical device company established in 2011, specializing in wearable insulin pumps using electroosmotic pump technology. It launched the disposable wearable insulin pump EOPatch in 2021, which offers superior convenience, waterproofing, and longer replacement intervals compared to existing products, securing a competitive edge in the diabetes medical device market. The company expanded into European markets in 2022 and is exploring diverse fields such as obesity and NASH treatments through non-insulin pump business. However, its non-insulin business has been halted due to a lawsuit with Insulet.

Number of Employees

51people

Average Salary

55.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
—Industry Average 1.203.5Point
ROE
—Industry Average 8.003.5Point
Debt Ratio
-5.38Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20251.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼25.4% (2-year basis)

Operating Profit Growth Rate
1.0 / 3

Avg ▲4.3% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -140.2% (declining, 2yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position4.0Point

52w mid range (50%)

Current 1,490Won52-week high 1,49052-week low 1,490
1-month return3.0Point

1m 0% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

13 totalPositive 4Neutral 8Negative 1
  • Neutral기타시장안내(최대주주의의무보유관련) (최대주주의 의무보유 이행 관련)2026-10-22
  • Negative소송등의판결ㆍ결정(일정금액이상의청구) (영업비밀보호법(“DTSA”)에 따른 영업비밀 침해 및 특허 침해 소송)2026-10-20
  • Neutral주요사항보고서(전환사채권발행결정)2026-10-15
  • Neutral주요사항보고서(자본으로인정되는채무증권발행결정)2026-10-15
  • Positive[기재정정]주요사항보고서(유상증자결정)2026-10-12